{
    "clinical_study": {
        "@rank": "134414", 
        "acronym": "MORE", 
        "arm_group": {
            "arm_group_label": "Control Group", 
            "description": "Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases"
        }, 
        "brief_summary": {
            "textblock": "Investigator initiated multi-institutional retrospective review of clinical and radiographic\n      outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver\n      metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks\n      follow up."
        }, 
        "brief_title": "Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project", 
        "condition": [
            "Colorectal Cancer", 
            "Liver Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Investigator initiated multi-institutional retrospective review of clinical and radiographic\n      outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver\n      metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks\n      follow up. Objectives:\n\n      Independent data collection and reporting of pre treatment and 12 week post treatment\n      clinical, radiographic and radiation parameters and outcomes in patients treated in the USA\n      from 2002-2010. Data beyond 12 weeks will be collected and highly desirable, however as a\n      minimum all patients will have 12 week follow up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received 90Y resin microsphere radioembolization for metastatic\n             colorectal cancer with liver metastases between November 2010 and March 2011 in the\n             USA. Patients must have at least 12 weeks of follow up.\n\n        Exclusion Criteria:\n\n          -  Patients who received glass 90Y microsphere radioembolization for metastatic\n             colorectal liver metastases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with colorectal liver metastases in the USA treated with 90Y resin microsphere\n        radioembolization"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815879", 
            "org_study_id": "MORE"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic colorectal cancer", 
            "liver metastases", 
            "90Y resin microsphere radioembolization", 
            "retrospective data analysis"
        ], 
        "lastchanged_date": "March 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Contact Sarah Cannon"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project", 
        "overall_official": {
            "affiliation": "SCRI Development Innovations, LLC", 
            "last_name": "Andrew S Kennedy, MD, FACRO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Multiple systems monitored for side effects possibly related to liver radiotherapy.", 
            "measure": "Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815879"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sarah Cannon", 
            "investigator_full_name": "Andrew Kennedy", 
            "investigator_title": "Principal Investigator and Sponsor-Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Pretreatment planning scans (-45 to -1 day) compared to post radiotherapy scans of the liver, PET/CT not recommended, prefer MRI with Gd or CT with contrast, 3 phase, with rescanning in similar fashion at day 90 post treatment.", 
            "measure": "Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Sarah Cannon", 
        "sponsors": {
            "collaborator": {
                "agency": "Sirtex Medical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Andrew Kennedy", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}